A randomized, open‐label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft‐tissue sarcoma

Background Therapeutic options for patients with advanced soft‐tissue sarcoma (STS) are limited. The goal of the current phase 2 study was to examine the clinical activity and safety of the combination of gemcitabine plus pazopanib, a multityrosine kinase inhibitor with activity in STS. Methods The...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer Vol. 127; no. 6; pp. 894 - 904
Main Authors:	Somaiah, Neeta, Van Tine, Brian Andrew, Wahlquist, Amy E., Milhem, Mohammed M., Hill, Elizabeth G., Garrett‐Mayer, Elizabeth, Armeson, Kent E., Schuetze, Scott M., Meyer, Christian F., Reuben, Daniel Y., Elias, Anthony D., Read, William L., Chawla, Sant P., Kraft, Andrew S.
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 15.03.2021
Subjects:	Adult Adverse events Aged Aged, 80 and over Anemia Anthracycline Antineoplastic Combined Chemotherapy Protocols - therapeutic use best overall response Confidence intervals Cross-Over Studies Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Docetaxel - administration & dosage Docetaxel - adverse effects Dosage Enzyme inhibitors Female Gemcitabine gemcitabine and pazopanib Health services Humans Hypertension Indazoles - administration & dosage Indazoles - adverse effects Inhibitor drugs Kinases Lymphopenia Male Median (statistics) Medical treatment Middle Aged Neutropenia Oncology Patients Pyrimidines - administration & dosage Pyrimidines - adverse effects Rank tests Safety Sarcoma Soft Tissue Neoplasms - drug therapy Soft Tissue Neoplasms - mortality soft‐tissue sarcoma Statistical analysis Sulfonamides - administration & dosage Sulfonamides - adverse effects Targeted cancer therapy Terminology Thrombocytopenia Young Adult adverse events soft-tissue sarcoma gemcitabine and pazopanib best overall response
ISSN:	0008-543X, 1097-0142, 1097-0142
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!